A Study of Ramantamig in Combination With Daratumumab With or Without Lenalidomide or of Single-agent JNJ-102299639 for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or Ramantamig in Combination With Pomalidomide for Multiple Myeloma (TRIlogy-2)
A Phase 1b Study of Ramantamig in Combination With Daratumumab With or Without Lenalidomide or of Single-agent JNJ-102299639 for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or Ramantamig With Pomalidomide for Multiple Myeloma
The primary purpose of this study for Part 1 (Dose Escalation) is to identify the safe effective dose (recommended Phase 2 doses [RP2Ds]) and schedule for ramantamig treatment regimens and JNJ-102299639 treatment regimens; and for Part 2 (Dose Expansion) is to further characterize the safety and tolerability of ramantamig and JNJ-102299639 treatment regimens at selected RP2D(s).
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 1
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Study Contact
- Telefonnummer: 844-434-4210
- E-Mail: Participate-In-This-Study1@its.jnj.com
Studienorte
-
-
-
Clayton, Australien, 3168
- Rekrutierung
- Monash Medical Centre
-
Fitzroy, Australien, 3065
- Rekrutierung
- St Vincents Hospital Melbourne
-
Melbourne, Australien, 3000
- Rekrutierung
- Peter MacCallum Cancer Centre
-
Waratah, Australien, 2298
- Rekrutierung
- Calvary Mater Newcastle Hospital
-
Wollongong, Australien, 2500
- Rekrutierung
- Wollongong Hospital
-
-
-
-
-
Haifa, Israel, 3436212
- Rekrutierung
- Carmel Medical Center
-
Ramat Gan, Israel, 52621
- Rekrutierung
- Sheba Medical Center
-
Tel Aviv, Israel, 64239
- Rekrutierung
- Tel Aviv Sourasky Medical Center
-
Yeruham, Israel, 9112001
- Rekrutierung
- Hadassah Medical Center
-
-
-
-
-
Amsterdam, Niederlande, 1081 HV
- Rekrutierung
- VU Medisch Centrum
-
Groningen, Niederlande, 9713 GZ
- Rekrutierung
- Universitair Medisch Centrum Groningen
-
Utrecht, Niederlande, 3584 CX
- Rekrutierung
- UMC Utrecht
-
-
-
-
-
Barcelona, Spanien, 08036
- Rekrutierung
- Hosp. Clinic de Barcelona
-
Salamanca, Spanien, 37007
- Rekrutierung
- Hosp Clinico Univ de Salamanca
-
-
-
-
Colorado
-
Denver, Colorado, Vereinigte Staaten, 80218
- Rekrutierung
- Colorado Blood Cancer Institute
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30322
- Rekrutierung
- Winship Cancer Institute Emory University
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria for newly diagnosed multiple myeloma (NDMM) and relapsed or refractory multiple myeloma (R/R MM):
- Have documented initial diagnosis of multiple myeloma according to IMWG diagnostic criteria
- Meet treatment regimen-specific requirements as follows: Treatment regimen A (ramantamig+daratumumab):Treatment regimens A1 and A3: Have been treated with 1 to 3 prior lines of therapy, including a proteasome inhibitor (PI) and an inhibitor, immunomodulatory drug (IMiD) therapy for the treatment of multiple myeloma (MM); Treatment regimens A2 and A4: Newly diagnosed MM naïve to multiple myeloma (or other related plasma cell neoplasm)-directed treatments; Treatment regimen B (ramantamig+pomalidomide): Have received greater than or equal to (>=) 1 prior line of therapy, including a PI and lenalidomide, and are lenalidomide refractory OR >=2 prior lines of therapy, including a PI and lenalidomide; Treatment Regimens C, D, E and H: Newly diagnosed MM naïve to multiple myeloma (or other related plasma cell neoplasm)-directed treatments
- Have a weight >=40 kilograms
- Must have an Eastern Cooperative Oncology Group status of 0 or 2
- Have measurable disease at screening as defined by at least 1 of the following: a) Serum monoclonal protein (M-protein) level >= 0.5 gram per deciliter (g/dL); or b) Urine M-protein level >=200 milligram (mg)/24 hours; or c) Light chain multiple myeloma: Serum immunoglobulin (Ig) free light chain (FLC) >= 10 mg/dL and abnormal serum Ig kappa lambda FLC ratio. d) For participants without measurable disease in the serum, urine, or involved FLC: presence of 1 or more focus of extramedullary disease which meets the following criteria: extramedullary plasmacytoma not contiguous with a bone lesion, at least 1 lesion >=2 centimeter (cm) (at its greatest dimension) diameter on whole body positron emission tomography-computed tomography (or whole-body magnetic resonance imaging approved by sponsor), and not previously radiated
Inclusion criteria for newly diagnosed amyloid light chain (ND AL) Amyloidosis
- Have a histopathological diagnosis of amyloidosis
- Have an ECOG performance status of 0 to 1
Inclusion criteria for High-risk smoldering multiple myeloma (SMM)
- Have a diagnosis of SMM (per IMWG criteria) for less than or equal to (<=) 5 years with measurable disease at the time of enrollment as defined in the protocol
- Have an ECOG performance status of 0 to 1
Exclusion Criteria for NDMM and R/R MM:
- Prior antitumor therapy as follows, in the specified time frame prior to the first dose of study treatment: a) Targeted therapy, epigenetic therapy, monoclonal antibody (mAb) treatment, or treatment with an investigational drug or an invasive investigational medical device within 21 days or 5 half-lives, whichever is less. b) Gene-modified adoptive cell therapy (example, chimeric antigen receptor [CAR] modified T cells, natural killer cells) within 90 days. c) Prior anti-CD38 directed therapy within 90 days (for treatment regimens A, C, D and E only; within 21 days for treatment regimen B). d) Conventional chemotherapy within 21 days. e) PI therapy within 14 days. f) Immunomodulatory agent therapy within 7 days. g) Radiotherapy within 14 days
- Stem cell transplantation: a) Allogeneic stem cell transplant within 6 months before the first dose of study treatment. b) Received an autologous stem cell transplant <=12 weeks before the first dose of study treatment
- Nonhematologic toxicity from prior anticancer therapy that has not resolved to baseline level or to grade <=1 (except alopecia, tissue post-RT fibrosis [any grade] or peripheral neuropathy grade <=3)
- Prior treatment with CD3-redirecting therapy
Exclusion Criteria for ND AL Amyloidosis
- Previous or current diagnosis of symptomatic multiple myeloma, including the presence of lytic bone disease, plasmacytomas, >=60 percent (%) plasma cells in the bone marrow, or hypercalcemia
- Macroglossia that impairs swallowing difficulty
- Prior therapy for AL amyloidosis or multiple myeloma
Exclusion Criteria for High-risk SMM
- Multiple myeloma, requiring treatment
- Primary systemic AL (immunoglobulin light chain) amyloidosis
Exclusion criteria for all participants:
- Any serious underlying medical conditions, such as: Evidence of active viral, bacterial, or systemic fungal infection requiring ongoing antiviral, antibacterial, or antifungal treatment; active autoimmune disease requiring systemic immunosuppressive therapy within 6 months before start of study treatment; cardiovascular dysfunction; pulmonary compromise requiring supplemental oxygen use to maintain adequate oxygenation; human immunodeficiency (HIV) infection; active hepatitis B or C infection; stroke or seizure within 6 months prior to first dose of study treatment
- Known or suspected chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) less than (<) 50 percent (%)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Sequenzielle Zuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Treatment Regimen A and C: Ramantamig+Daratumumab
Participants who have received 1-3 prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD) (Treatment regimen A1 and A3) will receive ramantamig along with daratumumab to establish the recommended phase 2 doses (RP2D[s]) of the ramantamig during Part 1 (Dose Escalation) of the study. Based on the study evaluation team (SET) decision, enrollment may proceed in participants with newly diagnosed multiple myeloma (NDMM) (Treatment regimens A2, A4 and C). Dose escalation and de-escalation will be based on SET evaluation. In Part 2 (Dose Expansion) participants will receive a dose of ramantamig combination treatment regimen(s) at the RP2D(s) determined in Part 1 and in disease subgroup(s) to determine the safety and tolerability of the combination treatment regimens. |
Daratumumab will be administered subcutaneously. Ramantamig will be administered subcutaneously. |
|
Experimental: Treatment Regimen B: Ramantamig+Pomalidomide
Participants who have received greater than or equal to (>=)1 prior line of therapy, including a PI and lenalidomide, and are lenalidomide refractory or >=2 prior lines of therapy, including a PI and lenalidomide will receive ramantamig along with pomalidomide to establish the RP2D(s) of the ramantamig during Part 1 (Dose Escalation) of the study. Dose escalation and de-escalation will be based on SET evaluation. In Part 2 (Dose Expansion) participants will receive a dose of ramantamig combination treatment regimen(s) at the RP2D(s) determined in Part 1 and in disease subgroup(s) to determine the safety and tolerability of the combination treatment regimens. |
Pomalidomide will be administered orally. Ramantamig will be administered subcutaneously. |
|
Experimental: Treatment Regimen D and E: Ramantamig + Daratumumab + Lenalidomide Combination
Participants with NDMM will receive ramantamig along with daratumumab and lenalidomide to establish the RP2D[s] of the ramantamig during Part 1 (Dose Escalation) of the study. Dose escalation and de-escalation will be based on SET evaluation. In Part 2 (Dose Expansion) participants will receive a dose of ramantamig combination treatment regimen(s) at the RP2D(s) determined in Part 1 and in disease subgroup(s) to determine the safety and tolerability of the combination treatment regimens. |
Lenalidomide will be administered orally. Daratumumab will be administered subcutaneously. Ramantamig will be administered subcutaneously. |
|
Experimental: Treatment Regimen F: Ramantamig+ Daratumumab
Participants with newly diagnosed amyloid light chain (ND AL) amyloidosis will receive ramantamig in treatment regimen F along with daratumumab to establish the RP2D[s] of the ramantamig during Part 1 (Dose Escalation) of the study. Dose escalation and de-escalation will be based on SET evaluation. In Part 2 (Dose Expansion) participants will receive a dose of ramantamig and daratumumab at the RP2D(s) determined in Part 1 and in disease subgroup(s) to determine the safety and tolerability of the combination treatment regimens. |
Daratumumab will be administered subcutaneously. Ramantamig will be administered subcutaneously. |
|
Experimental: Treatment Regimen G: Ramantamig + Daratumumab
Participants with high-risk smoldering multiple myeloma (SMM) will receive ramantamig in treatment regimen G along with daratumumab to establish the RP2D[s] of the ramantamig during Part 1 (Dose Escalation) of the study. Dose escalation and de-escalation will be based on SET evaluation. In Part 2 (Dose Expansion) participants will receive a dose of ramantamig and daratumumab at the RP2D(s) determined in Part 1 and in disease subgroup(s) to determine the safety and tolerability of the combination treatment regimens. |
Daratumumab will be administered subcutaneously. Ramantamig will be administered subcutaneously. |
|
Experimental: Treatment Regimen H: JNJ-102299639
Participants with NDMM in treatment regimen H will receive JNJ-102299639 to establish the RP2D[s] during Part 1 (Dose Escalation) of the study. Dose escalation and de-escalation will be based on SET evaluation. In Part 2 (Dose Expansion) participants will receive JNJ-102299639 at the RP2D(s) determined in Part 1 and in disease subgroup(s) to determine the safety and tolerability of the treatment regimens. |
JNJ-102299639 will be administered subcutaneously. |
|
Experimental: Treatment Regimen I: JNJ-102299639
Participants with ND AL Amyloidosis in treatment regimen I will receive JNJ-102299639 to establish the RP2D[s] during Part 1 (Dose Escalation) of the study. Dose escalation and de-escalation will be based on SET evaluation. In Part 2 (Dose Expansion) participants will receive JNJ-102299639 at the RP2D(s) determined in Part 1 and in disease subgroup(s) to determine the safety and tolerability of the treatment regimens. |
JNJ-102299639 will be administered subcutaneously. |
|
Experimental: Treatment Regimen J: JNJ-102299639
Participants with high-risk SMM in treatment regimen J will receive JNJ-102299639 to establish the RP2D[s] during Part 1 (Dose Escalation) of the study. Dose escalation and de-escalation will be based on SET evaluation. In Part 2 (Dose Expansion) participants will receive JNJ-102299639 at the RP2D(s) determined in Part 1 and in disease subgroup(s) to determine the safety and tolerability of the treatment regimens. |
JNJ-102299639 will be administered subcutaneously. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Part 1: Number of Participants with Dose-limiting Toxicity (DLT)
Zeitfenster: Up to 28 days
|
DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity. |
Up to 28 days
|
|
Number of Participants with Adverse Events (AEs) by Severity
Zeitfenster: Up to 3 Years and 3 months
|
An AE is any untoward medical occurrence in a clinical study participant that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Severity will be graded according to the national cancer institute common terminology criteria for adverse events (NCI-CTCAE) version 5.0. Severity scale ranges from grade 1 (mild) to grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening and Grade 5= death related to adverse event. |
Up to 3 Years and 3 months
|
|
Number of Participants with Clinically Significant Laboratory Abnormalities
Zeitfenster: Up to 3 Years and 3 months
|
Participants with clinically significant laboratory abnormalities (hematology and chemistry) will be reported. |
Up to 3 Years and 3 months
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of Participants With Overall Response Rate
Zeitfenster: Up to 3 Years and 3 months
|
Overall response rate is defined as percentage of participants with newly diagnosed multiple myeloma (NDMM), relapsed or refractory multiple myeloma (R/R MM), or high-risk smoldering multiple myeloma (SMM) who have a partial response (PR) or better evaluated by the investigator as per international myeloma working group (IMWG) 2016 criteria. |
Up to 3 Years and 3 months
|
|
Percentage of Participants With Very Good Partial Response (VGPR) or Better Response Rate
Zeitfenster: Up to 3 Years and 3 months
|
VGPR or better response rate is defined as the percentage of participants with NDMM, R/R MM, or high-risk SMM who achieve a VGPR or better response (stringent complete response [sCR]+ complete response [CR]+VGPR) according to the IMWG 2016 criteria. |
Up to 3 Years and 3 months
|
|
Percentage of Participants With CR or Better Response Rate
Zeitfenster: Up to 3 Years and 3 months
|
CR or better response rate is defined as the percentage of participants with NDMM R/R MM, or high-risk SMM who achieve a CR or better response (sCR+CR) according to the IMWG 2016 criteria. |
Up to 3 Years and 3 months
|
|
Percentage of Participants With sCR or Better Response Rate
Zeitfenster: Up to 3 Years and 3 months
|
sCR rate is defined as the percentage of participants with NDMM R/R MM, or high-risk SMM who achieve an sCR according to the IMWG 2016 criteria. |
Up to 3 Years and 3 months
|
|
Duration of Response (DOR)
Zeitfenster: Up to 3 Years and 3 months
|
DOR is defined as time from date of initial documentation of a response (PR or better) to date of first documented evidence of progressive disease (PD), as per IMWG 2016 response criteria, or death due to progression, whichever occurs first in participants with NDMM, R/R MM, or high-risk SMM. |
Up to 3 Years and 3 months
|
|
Time to Response (TTR)
Zeitfenster: Up to 3 Years and 3 months
|
TTR is defined as the time between date of first dose of study treatment and the first efficacy evaluation at which the participants with NDMM, R/R MM, or high-risk SMM has met all criteria for PR or better as defined by IMWG 2016 response criteria. |
Up to 3 Years and 3 months
|
|
Percentage of Participants With Hematologic Response As Defined by International Amyloidosis Consensus Criteria
Zeitfenster: Up to 3 Years and 3 months
|
Hematologic response is defined as percentage of participants with newly diagnosed amyloid light chain (ND AL) amyloidosis who achieve complete response, very good partial response, partial response, no response and progression as defined by International amyloidosis consensus criteria present in the protocol will be reported. |
Up to 3 Years and 3 months
|
|
DOR as Defined by International Amyloidosis Consensus Criteria
Zeitfenster: Up to 3 Years and 3 months
|
DOR is defined as time from date of initial documentation of a response (PR or better) to date of first documented evidence of progressive disease (PD), as per International amyloidosis consensus criteria, or death due to progression, whichever occurs first in participants with ND AL amyloidosis. |
Up to 3 Years and 3 months
|
|
TTR as Defined by International Amyloidosis Consensus Criteria
Zeitfenster: Up to 3 Years and 3 months
|
TTR is defined as the time between date of first dose of study treatment and the first efficacy evaluation at which the participant with ND AL amyloidosis has met all criteria for PR or better as defined by International amyloidosis consensus criteria. |
Up to 3 Years and 3 months
|
|
Serum Concentration of Ramantamig, Daratumumab, and JNJ-102299639
Zeitfenster: Up to 3 Years and 3 months
|
Serum samples will be analyzed to determine concentrations of ramantamig, daratumumab, and JNJ-102299639. |
Up to 3 Years and 3 months
|
|
Area Under the Serum Concentration Time Curve from Time Zero to Infinity (AUCinf) for Ramantamig, Daratumumab, and JNJ-102299639
Zeitfenster: Up to 3 Years and 3 months
|
AUCinf for ramantamig, daratumumab, and JNJ-102299639 will be reported. |
Up to 3 Years and 3 months
|
|
Area Under the Serum Concentration Time Curve from Time Zero to the Last Measurable Concentration [AUC(0-t)] for Ramantamig, Daratumumab, and JNJ-102299639
Zeitfenster: Up to 3 Years and 3 months
|
AUC(0-t) for ramantamig, daratumumab, and JNJ-102299639 will be reported. |
Up to 3 Years and 3 months
|
|
Area Under the Serum Concentration Time Curve During the Dosing Interval (AUCtau) for Ramantamig, Daratumumab, and JNJ-102299639
Zeitfenster: Up to 3 Years and 3 months
|
AUCtau for ramantamig, daratumumab, and JNJ-102299639 will be reported. |
Up to 3 Years and 3 months
|
|
Maximum Serum Concentration (Cmax) for Ramantamig, Daratumumab, and JNJ-102299639
Zeitfenster: Up to 3 Years and 3 months
|
Cmax for ramantamig, daratumumab, and JNJ-102299639 will be reported. |
Up to 3 Years and 3 months
|
|
Half Life (T1/2) for Ramantamig, Daratumumab, and JNJ-102299639
Zeitfenster: Up to 3 Years and 3 months
|
T1/2 for ramantamig, daratumumab, and JNJ-102299639 will be reported. |
Up to 3 Years and 3 months
|
|
Time to Reach Cmax (Tmax) for Ramantamig, Daratumumab, and JNJ-102299639
Zeitfenster: Up to 3 Years and 3 months
|
Tmax for ramantamig, daratumumab, and JNJ-102299639 will be reported. |
Up to 3 Years and 3 months
|
|
Systemic Clearance (CL/F) for Ramantamig, Daratumumab, and JNJ-102299639
Zeitfenster: Up to 3 Years and 3 months
|
CL/F for ramantamig, daratumumab, and JNJ-102299639 will be reported. |
Up to 3 Years and 3 months
|
|
Apparent Volume of Distribution at Steady State (Vss/F) for Ramantamig, Daratumumab, and JNJ-102299639
Zeitfenster: Up to 3 Years and 3 months
|
Vss/F for ramantamig, daratumumab, and JNJ-102299639 will be reported. |
Up to 3 Years and 3 months
|
|
Number of Participants with Presence of Anti-Drug Antibodies to Ramantamig, Daratumumab, and JNJ-102299639
Zeitfenster: Up to 3 Years and 3 months
|
Participants with anti-drug antibodies to ramantamig, daratumumab, and JNJ-102299639 will be reported. |
Up to 3 Years and 3 months
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Studienleiter: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Gefäßerkrankungen
- Herz-Kreislauf-Erkrankungen
- Neubildungen
- Stoffwechselerkrankungen
- Erkrankungen des Immunsystems
- Neubildungen nach histologischem Typ
- Hämatologische Erkrankungen
- Lymphoproliferative Erkrankungen
- Immunproliferative Erkrankungen
- Krebsvorstufen
- Neubildungen, Plasmazelle
- Hämostasestörungen
- Paraproteinämien
- Bluteiweißstörungen
- Hämorrhagische Störungen
- Proteostase-Mängel
- Hypergammaglobulinämie
- Amyloidose
- Ernährungs- und Stoffwechselerkrankungen
- Hämische und lymphatische Krankheiten
- Immunglobulin-Leichtketten-Amyloidose
- Schwelendes Multiples Myelom
- Multiples Myelom
- Organische Chemikalien
- Heterocyclische Verbindungen, 1-Ring
- Heterocyclische Verbindungen
- Heterocyclische Verbindungen, 2-Ring
- Heterocyclische Verbindungen, Fusionsring
- Carboxylsäuren
- Piperidine
- Phthalimides
- Phthalsäuren
- Säuren, carbocyclisch
- Piperidones
- Isoindolen
- Lenalidomid
- Pomalidomid
- Daratumumab
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 79635322MMY1002
- 2024-515316-44-00 (Registrierungskennung: EUCT number)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .